Research programme: prostate cancer therapy - Genta

Drug Profile

Research programme: prostate cancer therapy - Genta

Alternative Names: G 20000

Latest Information Update: 09 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genta
  • Developer Genta (CEASED)
  • Class Small molecules
  • Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Mixed function oxygenase inhibitors; Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 31 May 2004 Discontinued - Preclinical for Prostate cancer in USA (unspecified route)
  • 02 Oct 2003 This compound is still in active development (10K filings Dec 2002)
  • 22 Aug 2001 Preclinical development for Prostate cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top